Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06)

  1. Bellmunt, J.
  2. Trigo, J.M.
  3. Calvo, E.
  4. Carles, J.
  5. Pérez-Gracia, J.L.
  6. Rubió, J.
  7. Virizuela, J.A.
  8. López, R.
  9. Lázaro, M.
  10. Albanell, J.
Journal:
The Lancet Oncology

ISSN: 1470-2045

Year of publication: 2010

Volume: 11

Issue: 4

Pages: 350-357

Type: Article

DOI: 10.1016/S1470-2045(09)70383-3 GOOGLE SCHOLAR

Sustainable development goals